249 related articles for article (PubMed ID: 29376224)
21. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm.
Conte A; Fabbrini G; Belvisi D; Marsili L; Di Stasio F; Berardelli A
Eur J Neurol; 2010 Mar; 17(3):449-55. PubMed ID: 19968711
[TBL] [Abstract][Full Text] [Related]
22. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Safety and Efficacy of Botox and Neuronox in the Management of Benign Essential Blepharospasm: A Split-face Study.
Sane S; Ali MJ; Naik MN
Korean J Ophthalmol; 2019 Oct; 33(5):430-435. PubMed ID: 31612653
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of patients with frontalis sling operation in the treatment of essential blepharospasm unresponsive to botulinum toxin therapy.
Wabbels B; Roggenkämper P
Graefes Arch Clin Exp Ophthalmol; 2007 Jan; 245(1):45-50. PubMed ID: 16874524
[TBL] [Abstract][Full Text] [Related]
25. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
Lu R; Huang R; Li K; Zhang X; Yang H; Quan Y; Li Q
Am J Ophthalmol; 2014 Mar; 157(3):591-7.e1-2. PubMed ID: 24269849
[TBL] [Abstract][Full Text] [Related]
26. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
27. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
Sampaio C; Ferreira JJ; Simões F; Rosas MJ; Magalhães M; Correia AP; Bastos-Lima A; Martins R; Castro-Caldas A
Mov Disord; 1997 Nov; 12(6):1013-8. PubMed ID: 9399229
[TBL] [Abstract][Full Text] [Related]
28. Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years.
Streitová H; Bareš M
Acta Neurol Belg; 2014 Dec; 114(4):285-91. PubMed ID: 24604684
[TBL] [Abstract][Full Text] [Related]
29. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of focal dystonia with botulinum toxin A].
Sojer M; Wissel J; Müller J; Poewe W
Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.
Bladen JC; Feldman I; Favor M; Dizon M; Litwin A; Malhotra R
Eye (Lond); 2019 Mar; 33(3):349-352. PubMed ID: 30202071
[TBL] [Abstract][Full Text] [Related]
32. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm.
Bentivoglio AR; Fasano A; Ialongo T; Soleti F; Lo Fermo S; Albanese A
Eur J Neurol; 2009 Mar; 16(3):392-8. PubMed ID: 19364366
[TBL] [Abstract][Full Text] [Related]
33. Impact of botulinum toxin injections on quality of life and self-esteem in patients with blepharospasm.
Tang M; Li W; Ji F; Li X; Zhang Y; Liu P
Psychol Health Med; 2019 Jun; 24(5):513-518. PubMed ID: 30463432
[TBL] [Abstract][Full Text] [Related]
34. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience.
Silveira-Moriyama L; Gonçalves LR; Chien HF; Barbosa ER
Arq Neuropsiquiatr; 2005 Jun; 63(2A):221-4. PubMed ID: 16100966
[TBL] [Abstract][Full Text] [Related]
35. Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China.
Fang XB; Xie MS; Song ZB; Zhong ZG; Wang Y; Ou ZL; Dang C; Li L; Zhang WX
Neurol Sci; 2020 Mar; 41(3):645-652. PubMed ID: 31745757
[TBL] [Abstract][Full Text] [Related]
36. Experience with long-term treatment with albumin-supplemented botulinum toxin type A.
Mohammadi B; Kollewe K; Wegener M; Bigalke H; Dengler R
J Neural Transm (Vienna); 2009 Apr; 116(4):437-41. PubMed ID: 19319477
[TBL] [Abstract][Full Text] [Related]
37. Long-term adherence and response to botulinum toxin in different indications.
Lee JI; Jansen A; Samadzadeh S; Kahlen U; Moll M; Ringelstein M; Soncin G; Bigalke H; Aktas O; Moldovan AS; Waskoenig J; Jander S; Gliem M; Schnitzler A; Hartung HP; Hefter H; Albrecht P
Ann Clin Transl Neurol; 2021 Jan; 8(1):15-28. PubMed ID: 33259153
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
Jankovic J; Comella C; Hanschmann A; Grafe S
Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
[TBL] [Abstract][Full Text] [Related]
39. [Botulinum toxin therapy for focal dystonia].
Hahn K; Niklai E; Garzuly F; Szupera Z
Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
[TBL] [Abstract][Full Text] [Related]
40. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
